Welcome to our dedicated page for Cassava Sciences news (Ticker: SAVA), a resource for investors and traders seeking the latest updates and insights on Cassava Sciences stock.
Cassava Sciences, Inc. (SAVA) is a clinical-stage biotechnology company pioneering Alzheimer's disease research through therapeutic candidate simufilam and diagnostic tool SavaDx. This page aggregates official press releases, regulatory updates, and material event announcements directly from the company and verified sources.
Investors and researchers will find timely updates on Phase 3 clinical trial progress, FDA communications, intellectual property developments, and peer-reviewed study publications. Our curated feed ensures access to SAVA's critical milestones in drug development and diagnostic innovation without promotional commentary.
Key content categories include clinical trial results, partnership announcements with research institutions, financial disclosures related to R&D funding, and scientific presentations at major medical conferences. All materials are organized chronologically to track the company's evolving research narrative.
Bookmark this page for streamlined monitoring of Cassava Sciences' advancements in Alzheimer's therapeutics. For comprehensive analysis, cross-reference updates with SEC filings and scientific publications linked in source materials.
Cassava Sciences, focused on Alzheimer's disease, reported a net loss of $5.1 million for Q2 2021, translating to $0.13 per share, compared to a net loss of $1.1 million or $0.05 per share in Q2 2020. Cash and cash equivalents increased to $278.3 million as of June 30, 2021, with no debt. The expected cash usage for the full year is $20-25 million, driven by R&D and operational costs. R&D expenses surged to $3.9 million from $0.6 million year-over-year, reflecting a focus on clinical trial preparations.
Cassava Sciences, Inc. (Nasdaq: SAVA) will announce its financial results for Q2 2021 on August 3, 2021, before market opening. A conference call led by President & CEO Remi Barbier and CFO Eric Schoen will follow at 9 a.m. ET to discuss the results and growth strategy. Alzheimer's disease affects nearly 50 million people globally, with costs exceeding $1 trillion annually. The company is committed to developing innovative solutions for neurodegenerative conditions. Investors can access the event via the company’s website.
Cassava Sciences announced significant improvements in biomarkers for Alzheimer’s patients after 6 months of treatment with its investigational drug, simufilam. The study, involving 25 patients, showed a reduction in key biomarkers: total tau decreased by 38% and phosphorylated tau by 18% (both p<0.00001). Neurodegeneration markers neurogranin and NfL dropped by 72% and 55%, respectively (both p<0.00001). These biomarker improvements correlate with cognitive enhancements, supporting the drug's potential as a durable treatment.
Cassava Sciences (Nasdaq: SAVA) reported promising interim results from an open-label study of its investigational drug, simufilam, for Alzheimer's treatment. At 9 months, patients showed a significant cognitive improvement of 3.0 points on the ADAS-Cog scale (p<0.001), alongside notable biomarker enhancements. Importantly, over 50% of participants experienced no behavioral disorders, and no safety concerns were raised. The study, funded by NIH, involved 50 patients with mild-to-moderate Alzheimer's. Findings suggest simufilam has potential long-term benefits, warranting further Phase 3 trials set to commence in Fall 2021.
Cassava Sciences (Nasdaq: SAVA) announced positive clinical results from its SavaDx diagnostic in detecting Alzheimer’s disease. In a Phase 2b trial, treatment with simufilam significantly reduced plasma levels of altered filamin A by 48% (p=0.003) for 100 mg and 44% (p=0.02) for 50 mg doses. Additionally, p-tau181 levels decreased by 17% (p=0.01) and 15% (p=0.02) respectively. These findings suggest effective target engagement by simufilam. A poster presentation of these results was made at the Alzheimer’s Association International Conference (AAIC).
Cassava Sciences (Nasdaq: SAVA) is set to present new clinical data for its Alzheimer's candidates, SavaDx and simufilam, at the 2021 Alzheimer’s Association International Conference in Denver from July 26-30. A poster presentation on July 26 will detail SavaDx, while an oral presentation on July 29 will cover interim safety and cognitive results from the first 50 patients in a 9-month trial of simufilam. Key biomarkers will also be presented, crucial for understanding the drugs' mechanisms of action and potential in Alzheimer's treatment.
Cassava Sciences has appointed Premier Research International as its clinical research organization to lead the Phase 3 clinical program for simufilam, aimed at treating Alzheimer's disease. The company plans to initiate this pivotal program in the second half of 2021. With extensive experience in neuroscience, Premier Research will support Cassava in advancing simufilam into critical testing phases. This collaboration marks a significant step forward for Cassava as it seeks to address the pressing need for effective Alzheimer's therapies.
Cassava Sciences, Inc. (Nasdaq: SAVA) announced significant progress in its clinical development of simufilam for Alzheimer's disease. The open-label study successfully enrolled 150 subjects, and results from interim analyses will be presented at the Alzheimer's Association International Conference (AAIC) in July. The Cognition Maintenance Study has commenced with a 30% enrollment rate. Cassava plans to initiate a Phase 3 program in the latter half of 2021, supported by around $282 million in cash. The ongoing research is backed by NIH grants, emphasizing the company's commitment to developing innovative treatments.
Cassava Sciences (Nasdaq: SAVA) announced its participation in the Raymond James 2021 Human Health Innovation Conference. The virtual event is scheduled for June 21-23, 2021.
Management, including President & CEO Remi Barbier and CFO Eric Schoen, will deliver a corporate overview on June 22 at 3:20 PM ET. They will also engage with institutional investors throughout the conference. A replay of the presentation will be accessible until September 20, 2021 on the company's website under the ‘Investors’ tab.
Cassava Sciences, Inc. (Nasdaq: SAVA) announced the appointment of Mr. Richard Barry to its Board of Directors as of June 11, 2021. Mr. Barry, an experienced investor and former managing partner at Eastbourne Capital Management, will provide insights on sustainability and governance. His appointment aims to bolster the company's commitment to societal goals while progressing towards a Phase 3 clinical program for Alzheimer’s disease. Mr. Barry holds 150,000 shares of SAVA, underscoring his confidence in the company’s mission.
FAQ
What is the current stock price of Cassava Sciences (SAVA)?
What is the market cap of Cassava Sciences (SAVA)?
